

TG THERAPEUTICS, INC.  
Form 8-K  
June 18, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **June 18, 2015**

**TG Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

**001-32639**

**36-3898269**

(State or Other Jurisdiction (Commission File Number)

(IRS Employer Identification No.)

of Incorporation)

**3 Columbus Circle, 15<sup>th</sup> Floor**

**New York, New York 10019**

(Address of Principal Executive Offices)

**(212) 554-4484**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 8.01.**

**Other Events.**

On June 18, 2015, TG Therapeutics, Inc. issued a press release announcing updated clinical results from its Phase 2 study of TG-1101 (ublituximab) in combination with ibrutinib. The updated results from the Phase 2 study were delivered in an oral presentation by Dr. John Burke, Rocky Mountain Cancer Associates/US Oncology, Aurora, CO during the 13th International Congress on Malignant Lymphoma (ICML), being held from June 17 to June 20, 2015 in Lugano, Switzerland. A copy of the press release is being filed as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01**

**Financial Statements And Exhibits.**

(d)

Exhibits.

99.1

Press Release, dated June 18, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics,  
Inc.  
(Registrant)

Date: June 18, 2015

By: /s/ Sean A.  
Power  
Sean A.  
Power  
Chief  
Financial  
Officer

INDEX TO EXHIBITS

**Exhibit**

**Number Description**

99.1 Press Release, dated June 18, 2015.